Nanjing Entai Pharmaceutical Technology Co., Ltd.

Primary objective: To evaluate the effectiveness of amisulpride injection in preventing postoperative nausea and vomiting, and to provide a basis for the registration application of this product. Secondary objectives: 1) To evaluate the safety of amisulpride injection in preventing postoperative nausea and vomiting. 2) To evaluate the pharmacokinetic characteristics of amisulpride injection in preventing postoperative nausea and vomiting in Chinese patients.

Main study objectives To study the pharmacokinetic characteristics of a single infusion of the test preparation aprepitant injection (specification: 18mL:130mg) and the reference preparation aprepitant injection (CINVANTI®, specification: 18mL:130mg) in healthy subjects and evaluate the bioequivalence of the two preparations. Secondary study objectives To study the safety of the test preparation aprepitant injection 18mL:130mg and the reference preparation "CINVANTI®" 18mL:130mg in healthy subjects and to evaluate the bioavailability correlation of the two administration methods.